Intimation of execution of Business Transfer Agreement by RPG Active Pharma Limited (WOS) with Raghava Life Sciences Private Limited for Acquisition of API Business.

September 2, 2026 National Stock Exchange of India Limited BSE Limited Plot No. C/1, “G” Block, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai 400 001 Symbol: RPGLIFE Security Code: 532983 Dear Sirs /Madam, Sub: Outcome of Board Meeting Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at its meeting held today, i.e., Wednesday, September 02, 2026, inter alia, considered and approved the execution of Business Transfer Agreement by its wholly owned subsidiary, RPG Active Pharma Limited with Raghava Life Sciences Private Limited for acquisition of Active Pharmaceutical Ingredients (APIs) and intermediates Businesses as a going concern, by way of slump sale. The details required pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026 is given in Annexure A to this letter. The Board Meeting commenced at 7.00 pm and concluded at 8.10 pm. Yours sincerely, For RPG Life Sciences Ltd Rajesh Shirambekar Head – Legal & Company Secretary. Encl: as above. Annexure A Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Business Transfer Agreement between RPG Active Pharma Limited, a wholly owned subsidiary of the Company and Raghava Life Sciences Private Limited. Sr. No. Particulars Details 1 Name of the target entity, details in brief RPG Active Pharma Limited (“RPGAP”), the wholly such as size, turnover etc. owned subsidiary company of the Company, to acquire API and Intermediates Business Undertaking of Raghava Life Sciences Private Limited (“Raghava”) through a Business Transfer Agreement on a going concern basis by way of slump sale. The transaction includes business with revenues of about Rs. 19 Crores in FY26 (unaudited) along with manufacturing facilities, R&D facility and portfolio of 29 API molecules of which 22 are commercialized and 7 are under development. No shares are being purchased in any entity and no entity is being acquired. 2 Whether the acquisition would fall within No. related party transaction(s) and whether the promoter/ promoter group/ group The Promoter / Promoter Group / Group companies have any interest in the entity Companies have no interest in the entity whose being acquired? If yes, nature of interest assets are being acquired. and details thereof and whether the same is done at “arm’s length” 3 Industry to which the entity being The Business being acquired pertains to incorporated / acquired belongs Pharmaceutical Industry. 4 objects and impact of acquisition The acquisition is in line with the Company’s (including but not limited to, disclosure strategy to expand its API business through its of reasons for acquisition of target entity, subsidiary Company. if its business is outside the main line of business of the listed entity) 5 Brief details of any governmental or The transaction is subject to regulatory approvals, regulatory approvals required for the including approvals from local authorities, etc. acquisition 6 indicative time period for completion of It is expected that the transaction will be the acquisition completed tentatively within 30 days or such period as may be mutually agreed, subject to satisfaction of closing conditions. 7 Consideration - whether cash Cash Consideration consideration or share swap and details of the same 8 Cost of acquisition and/or the price at Since, this is a BTA transaction, business assets which the shares are acquired; are being acquired and not shares of any entity. The transaction proposed does not involve 9 Percentage of shareholding / control by acquisition of shares. the listed entity and / or number of shares allotted. The subject transaction is for consideration up to Rs. 135 crores (Rupees One Hundred and Thirty- Five crores) subject to customary adjustments and applicable taxes. 10 brief background about the entity Raghava Life Sciences Private Limited owns and acquired in terms of products/line of operates the business of development and business acquired, date of incorporation, manufacturing of active pharmaceutical history of last 3 years turnover, country ingredients (APIs) and intermediates. Besides, in which the acquired entity has Raghava was also into Contract Research presence and any other significant Organization (CRO) / Contract Research and information (in brief); Manufacturing Services (CRAMS) business (which is not being acquired). Since this transaction pertains to purchase of Business, and not an acquisition of an entity, the disclosure of 3 years turnover, percentage of shareholding and number of shares, would not be applicable.